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Available online 24 November 2016Mepolizumab, a humanized IgG1monoclonal antibody that blocks native homodimeric interleukin-5 (IL-5) from
binding to the IL-5 receptor, has recently been approved for treatment of severe eosinophilic asthma. Our initial
immunogenicity assay method for phase I and II studies utilized a bridging electrochemiluminescence format
with biotin and ruthenium-labelled mepolizumab linked by anti-drug antibodies (ADA). We discovered that
IL-5 signiﬁcantly increased in dosed subjects from a phase II study and that the increased IL-5 was in the form
of a drug-bound complex.We demonstrated that the elevated drug-bound IL-5 produced false-positive response
in the in vitro ADA assay, in which drug-bound IL-5 dissociated and then bridged mepolizumab conjugates to
yield positive signal. To eliminate the IL-5 interference, we compared two strategies: a solid-phase
immunodepletion of IL-5 and an in-solution IL-5 immunocompetition. We identiﬁed the best competitive anti-
body for each purpose.We found bothmethods demonstrated similar effectiveness in reducing the false positive
signal in IL-5 spiked samples; however, the in-solution immunocompetition for IL-5 had fewer false positives in
study samples. Additionally, the in-solution immunocompetitionmethodwas experimentally simpler to execute.
Wemodiﬁed the ADA assay by adding a pre-treatment stepwith amepolizumab competitive anti- IL-5 antibody.
Using this new method, we retested clinical samples from two phase II studies (MEA112997 and MEA114092).
The conﬁrmed ADApositive incidencewas reduced from29% and 61% to 1% and 8%with themodiﬁed in-solution
immune inhibition method. Target interference is a fairly common problem facing immunogenicity testing, and
target-induced false positive cannot be distinguished from true ADA response by the commonly used drug com-
petitive conﬁrmation assay. The approach and method used here for resolving target interference in ADA detec-
tion will be useful for differentiating between a true ADA response and target induced false positive as well as
similar challenges in other programs.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Mepolizumab1. Introduction
Mepolizumab is a humanized IgG1 monoclonal antibody that blocks
human IL-5 from binding the IL-5 receptor and has been an effective treat-
ment to reduce the risk of asthmatic exacerbations in patients with severe
eosinophilic asthma (Bel et al., 2014; Ortega et al., 2014; Pavord et al.,
2012; Pouliquen et al., 2015). However, the administration of a therapeutic
protein (biologic) is often associated with unwanted immune responses.
Potential clinical consequences of immunogenicity range from no or little
effect, altered PK or efﬁcacy, to severe adverse events (Koren et al., 2002;
Schellekens and Casadevall, 2004; Wolbink et al., 2009; Casadevall et al.,
2002; Li et al., 2001). The strategy formeasuring ADA involves clinical sam-
ple analysis with a sensitive screening assay, followed by a conﬁrmationeland Road, King Of Prussia, PA
. This is an open access article underassay. Those clinical samples conﬁrmedaspositive are further characterized
with titration, isotyping, orneutralization analysis. Ligandbinding immuno-
assay platforms, including enzyme-linked immunosorbent assay (ELISA)
and electrochemiluminescent immunoassays (ECLIA) are often used as
screening assays to detect antibodies directed against biotherapeutics. The
bridging immunoassay with the electrochemiluminescent (ECL) detection
is an efﬁcient approach with superior sensitivity and good drug tolerance
for the detection of anti-drug antibodies. However, the ECL bridging immu-
noassay is susceptible to interference from biological components that can
inhibit or crosslink the labelled drug to generate either a false negative or
false positive result, respectively. In theADAscreening assay, themost com-
mon interference that can lead to a false negative is the drug itself. On the
other hand, the interference factors that lead to a false ADA positive result
can be of many sources, including rheumatoid factor - human antibodies
against the Fc region of human IgG (Tatarewicz et al., 2010; Araujo et al.,
2011), multivalent target interference (Zhong et al., 2010; Schwickart et
al., 2014), soluble target receptors (Dia et al., 2014), and membranethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mind that aforementioned drug targets can also result in false-negative
ADAdetection, depending on the assay format aswell as the concentration,
structure, and chemical and biological properties of the targets. Therefore, it
is important to evaluate and understand the impact of drug intended tar-
gets and other relevant biological components for each ADA assay.
IL-5 is produced by a number of cell types and regulates multiple
major eosinophil functions, including cellular proliferation, maturation,
and mobilization from the bone marrow into the peripheral circulation
(Takatsu and Nakajima, 2008; Schrezenmeier et al., 1993; Mishra et al.,
2002; Kuo et al., 2001). Overexpression of IL-5 has been associated with
the increase of eosinophils in allergic diseases, including asthma (Hamid
et al., 1991; Yamamoto et al., 2003). For example, normal subjects had
less than 1 pg/mL IL-5, while asthmapatients exhibiting acute asthmatic
attacks had approximately 5 fold more (4.8 pg/mL) (Lee et al., 2001).
During the early development of the ADA assay for mepolizumab, we
tested for the interference of endogenous IL-5 in serum and observed
that IL-5 levels in asthma subjects tested negative (i.e. they did not
give a false positive result in the ADA assay). In the early phase I and II
clinical studies with mepolizumab, the observed ADA positive rate
was close to 50%. However; these elevated ADA positive incidences
did not correlate with decreased PK/PD or increased adverse events.
Since IL-5 levels were not evaluated in early mepolizumab clinical stud-
ies, the impact of mepolizumab on free and drug-bound IL-5 levels was
unknown until the two phase II studies (MEA112997/NCT01000506,
MEA114092/NCT01366521).
Utilizing two biomarker assays, a total IL-5 biomarker assay which
measured both unbound IL-5 (free) and drug-bound IL-5 and a free IL-
5 biomarker assay which measured only the free IL-5, we found that
IL-5 was signiﬁcantly increased in dosed subjects compared to pre-
dose samples and the elevated IL-5was in the form of drug-bound com-
plex.With this new information,we suspected that the elevated total IL-
5 levels in treated subjects contributed to the increased ADApositive in-
cidence observed in early studies by forming bridges with conjugated
drug in the assay. In this study, we tested our hypothesis of IL-5 induced
false positive ADA responses with both spiked serum and clinical sam-
ples.We evaluated two distinct strategies to overcome the IL-5 assay in-
terference: a solid-phase immunodepletion of IL-5 and an in-solution
IL-5 immunocompetition. We resolved IL-5 interference in the ADA
assay by adding a competitive therapeutic target antibody to the assay
solution. With the improved ADA assay, we re-analysed last two
phase II study samples. The ADA positive incidences were single digit
percentages compared to values close to 50% observed with original
ADA assay. This study highlights the importance of a parallel biomarker
readout and a careful examination of drug target interference in both
assay development phase and clinical sample testing phase.
2. Materials and methods
2.1. Reagents
Mepolizumab and recombinant human IL-5 were provided by
GlaxoSmithKline (GSK) BioPharm CMC. The rhIL-5 was biotinylated at
a biotin molar challenge ratio of 20:1with EZ-Link™ Sulfo-NHS-LC-Bio-
tin (Pierce, Waltham, MA) following the manufacturer's instruction;
rhIL-5 conjugated beads for ﬂow assay were generated using BD™
CBA functional beads and conjugation buffer set (BD Bioscience, San
Jose, CA) following the manufacturer's procedures. Biotin (Pierce, Wal-
tham,MA ) and ruthenium (MSD, Bethesda,MD) labelledmepolizumab
conjugates were produced according to themanufacturer's instructions
(8:1 for biotinylation and 15:1 for ruthenium labelling, respectively).
Read Buffer T (R92TC-1), ruthenium labelled streptavidin, streptavidin
coated plates were purchased from MSD (Bethesda MD). Nunc 96-
well plates, streptavidin agarose were purchased from Thermo Fisher
Scientiﬁc (Waltham,MA). The positive control (PC)was afﬁnity puriﬁed
hyper-immunized rabbit sera at Covance (Chantilly, VA). The negativecontrol (NC) was generated by pooling 65 normal human serum sam-
ples that had below cut point response in the initial ADA assay. Other
buffer reagents including PBS, PBST (1× PBS with 0.1% Tween 20) was
prepared by GSK Media Prep; BSA and azide were purchased from
Sigma Aldrich (St. Louis, MO).
2.2. Human serum
A normal human serum panel was purchased from BioReclaimation.
Study serum samples used for assay development purposes were from
clinical study NCT01000506/MEA112997, and usedwithin the ICF spec-
iﬁcations. Additional studies include NCT01366521/MEA114092,
NCT01691508/MEA115575, NCT01691521/MEA115588 and
NCT01842607/MEA115661.
2.3. Anti IL-5 antibodies
A total of 16 different IL-5 antibodies were purchased from various
vendors: LS-C50743 from LifeSpan BioSciences (Seattle, WA); CS-
7887, SC-8433, SC-34812, and SC-34814 from Santa Cruz Biotechnology
(Dallas, TX); MM550C and MM550CB from Thermo Fisher Scientiﬁc
(Waltham,MA); MAB205, MAB605, and AB-205-NA from R&D Systems
(Minneapolis, MN); 554491 from BD Biosciences (San Jose, CA);
CSI10100 from Cell Sciences (Newburyport, MA); 10118-08, 10118-
01,10119-01 and 10206-01 from Southern Biotech (Birmingham, AL).
2.4. IL5 biomarker assay
Total IL-5 was measured on the Meso Scale Discovery platform, and
used commercial sources for both the capture (10118-01) and detection
(clone TRFK5, cat#MM550CB) antibodies. Recombinant IL-5 was used
as the calibrator. The assay was designed to detect both free IL-5 and
drug-bound IL-5. Brieﬂy, assay plates were coated overnight with cap-
ture antibody at 5 μg/mL with 1× PBS. Plates were then blocked at
room temperature (RT) for 1 h with 3%BSA/PBS. Calibrators, controls,
and samples were 1:1 diluted in buffer (6.4 mM EDTA, 5.1 mM EGTA,
50 mM HEPES, 149.2 mM NaCl, 1% Triton X-100, 1% BSA, pH 7.4), and
then 50 μL of the diluted samples were added to the assay plate and in-
cubated at RT for 2 h. After washing, 50 μL of detection solution contain-
ing 2 μg/mL of detection antibody (biotin labelled TRFK5) and 0.5 μg/mL
ruthenium labelled streptavidin were added to eachwell and incubated
for 1.5 h. Plates were washed and 2× Read buffer was added before
reading on the MSD SECTOR Imager 6000. The measurement of IL-5
was tolerant to 100 μg/mL mepolizumab and therefore the assay was
deemed ﬁt-for-purpose for total IL-5 detection. The validated quantiﬁ-
able range was 7.8–500 pg/mL. All samples and calibrators were run
in duplicate, and a four parameter logistic curve was used to convert
the MSD counts into concentration units (pg/mL).
2.5. Initial ADA screening assay
For the initial ADA screening method, serum samples were diluted
1:10 in assay diluent (0.5% BSA in PBS with 0.05% Tween 20 and 0.05%
Azide) and then 1:1 with biotin and sulfo-tag drug conjugates (ﬁnal
concentrations for each conjugatewere 0.25 μg/mL) for an overnight in-
cubation at RT under gentle agitation (300 rpm). The sample/conjugate
solutions (50 μL/well) were then added to a blocked (3% BSA in PBST)
streptavidin-coatedMeso Scale plate and allowed to incubate for an ad-
ditional hour at RT with gentle agitation.Wells were washed with PBST
(3 × 300 μL), and then received 1× Read Buffer T. Plates were read on a
Meso Scale Sector Imager 6000. The mean signal from duplicate wells
were normalized to the signal from the negative control on the plate,
and referred to as relative ECL (RECL). This method was validated for
clinical sample testing at a CRO. Samples above the cut point (RECL =
1.58)were further conﬁrmed by free drug competition assay. Conﬁrma-
tion cut point (=30.3%) was established to allow for 1% false positive
Fig. 1. IL-5 levels in ADA negative and ADA positive groups from initial ADA assay.
Table 1
IL-5 levelswere elevated inmepolizumab dosed samples. Values below the Lower Limit of
Quantiﬁcation (LLQ)were imputed using LLQ/2. LLQ value: 7.8 pg/mL. BLQ: Below Level of
Quantiﬁcation.
Mepolizumab (mg)
Placebo 75 250 750
Baseline n 154 150 144 156
Mean (pg/mL) 4.7 6.5 4.5 8.7
BLQ n (%) 148 (96%) 143 (95%) 136 (94%) 148 (95%)
Week 16 n 146 151 147 152
Mean (pg/mL) 14.2 110.4 111.1 101.6
BLQ n (%) 136 (93%) 14 (9%) 6 (4%) 7 (5%)
Week 48 n 133 133 136 140
Mean (pg/mL) 10.5 107.8 98.7 91.1
BLQ n (%) 121 (91%) 11 (8%) 6 (4%) 4 (3%)
Week 56 n 5 6 4 5
Mean (pg/mL) 3.9 65.8 69.9 61.6
BLQ n (%) 5 (100%) 1 (17%) 0 0
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with simulation modelling by a GSK statistician using inhibition data
from 20 naïve sera and 20 low level PC spiked sera from multiple runs
by multiple analysts during validation, a decrease of assay response of
30.3% or greater was deemed as a drug-speciﬁc ADA response.
2.6. Anti-IL-5 antibody competition evaluation
To evaluate commercial anti-IL-5 antibodies and mepolizumab for
relative competition for IL-5 binding, two different methods were ap-
plied: ﬂow based competition and plate based competition assay.
2.6.1. Flow based competition assay
For ﬂow based target competition, IL-5 was conjugated on BD func-
tional beads following manufacturer's instruction and the success of
conjugation was conﬁrmed by binding to mepolizumab followed by
PE labelled mouse anti-human IgG detection (BD bioscience, San Jose,
CA). Mepolizumab titration determined a minimum concentration
reaching plateau of ﬂuorescent signal of 2 μg/mL. For mepolizumab
binding competition, 10 μg/mL of test anti-IL-5 antibodies were pre-in-
cubated with IL-5 beads at RT for 10 min, then followed by addition of
mepolizumab to ﬁnal concentration of 2 μg/mL and incubated at RT
for 15 min. Samples were washed once with 1% BSA /PBS buffer. Beads
were resuspended with 100 μL staining buffer (1%BSA/PBS) and added
20 μL PE labelled mouse anti human IgG and then incubated at RT for
10 min. The beads were washed once with 1% BSA/PBS buffer and
analysed on BD Calibur (San Jose, CA). For each assay, buffer replacing
test anti-IL-5 antibody was included to obtain maximum signal. A de-
crease of ﬂuorescent signal (MFI, mean ﬂuorescent intensity) in the
presence of test IL-5 antibody indicated a competition binding between
the test anti-IL-5 antibody and mepolizumab. A percentage inhibition
was calculated for each test antibody with formula % inhibition =
100 ∗ (MFIbuffer−MFItest antibody)/MFIbuffer. The higher the % inhibition
indicated a more competitive test antibody.
2.6.2. Plate based competition assay
Anti-IL-5 antibodies at concentration of 20 μg/mL or 1 μg/mL were
pre-incubated with equal volume of 62.5 ng/mL biotinylated IL-5 for
1 h at RT. Then mixed with an equal volume of 62.5 ng/mL sulfo tagged
mepolizumab and continued to incubate at RT for additional 1 h. At the
end of the incubation, samples were transferred to 3% BSA/PBST (1×
PBS with 0.1% Tween-20) blocked streptavidin plate, and incubated at
RT for 1 h. Plates were washed with PBST (PBS with 0.1% Tween-20),
and then received 1× Read Buffer T. Plates were read on a Meso Scale
SECTOR Imager Reader. For each plate, a buffer control without anti-
IL-5 antibody provided the maximum signal for competition compari-
son. A decrease of assay response (ECL) indicated a competition of the
test IL-5 antibody with mepolizumab and suggested that the test anti
IL-5 antibody bound to a similar epitope region as mepolizumab.
2.7. Inhibition of IL-5 interference by solid phase extraction
To evaluate the efﬁciency of IL-5 removal from serum samples, free
or biotin labelled anti-IL-5 antibodies were coated onto regular 96-
well plate or streptavidin plates. For free anti-IL-5 antibody coating, an-
tibodies were diluted to 1 μg/mL in PBS, and 100 μL antibody solutions
were added to each well for overnight incubation at 4 °C. The biotin la-
belled anti-IL-5 antibodies were diluted to 1 μg/mL in PBS, with 100 μL
added to each well for 1.5 h incubation at RT. Both free and biotin la-
belled anti-IL-5 antibody coated plateswere blockedwith blocking buff-
er for 1.5 h. Serum samples spiked with either 500 ng/mL IL-5 or IL-5
plus 100 ng/mL drug were diluted 1:10 in diluent, with 100 μL added
to each well of the anti IL-5 antibody coated plates and incubated at
RT for 4 h. The IL-5 depleted samples (60 μL) were removed from the
wells and mixed with equal volume of drug conjugates for continuing
ADA detection with the initial ADA assay.To enhance capture mobility and increase antibody concentrations,
streptavidin agarose resin replaced streptavidin plates in method evalu-
ation with clinical samples. The biotinylated monoclonal antibody
(554491) was coated to streptavidin agarose resin: 450 μL resin was
mixed with 160 μL of 500 μg/mL antibody for overnight incubation at
RT in 5 mL PBS. Coated beads were washed and resuspended in 15 mL
assay diluent. For IL-5 depletion, samples were diluted (1:5) with
assay diluents, and then combinedwith equal volume of anti-IL-5 coated
resin slurry. The mixed sample and resin solution was agitated for 4 h
and then centrifuged for 10min to remove 80 μL supernatant. The super-
natant (IL-5 depleted samples) was thenmixedwith an equal volume of
drug conjugates which continued the initial ADA screening assay.
2.8. Inhibition of IL-5 Interference by addition of IL-5 blocking antibody
To reduce IL-5 induced ADA false positive results, samples were pre-
incubated with a mepolizumab competitive monoclonal antibody
(Mab205) at RT for 3 h before screening with the initial ADA assay.
Brieﬂy, samples were ﬁrst diluted (1:1) with an equal volume of assay
diluent (0.5% BSA in PBS with 0.05% Tween 20 and 0.05% azide); then
further diluted (1:5) with antibody blocking buffer (assay diluent con-
taining 50 μg/mL Mab205 IL-5 blocking antibody and 12.5% normal
human serum); and incubated at RT. After a 3 h pre-incubation with
IL-5 blocking antibody, the samples were diluted (1:1) with assay dilu-
ent (for the conﬁrmation analysis, this also contained 100 μg/mL drug).
Then, the samples were diluted (1:1) with equal concentrations of bio-
tin and sulfo-tag labelled mepolizumab (ﬁnal conjugate concentrations
were 0.25 μg/mL) for gentle agitation overnight at RT. Sample/conjugate
solutions (50 μL/well)were transferred to a blocked streptavidin-coated
Meso Scale plate and allowed to incubate for an additional hour at RT.
Fig. 3. Evaluation of anti-IL-5 antibody competition against mepolizumab on a plate based
assay. Anti-IL-5 antibodies at concentration of 20 μg/mL or 1 μg/mL were pre-incubated
with equal volume of 62.5 ng/mL of Bt-IL5 for 1 h at RT, then mixed with 62.ng/mL
sulfo-tagged mepolizumab and continued to incubate at RT for additional 1 h. At end of
the incubation, samples were transferred to 3% BSA/PBST blocked SA plate, incubated at
RT for 1 h. Plates were washed with PBST, and 1× MSD read buffer was added. Plates
were read on a Meso Scale Sector Imager Reader.
Table 2
IL-5 induced ADA false positive which conﬁrmed by 100 μg/mL mepolizumab. Results re-
ported as RECL, using a cut point of 1.58 RECL established for disease population.
Mepolizumab
(μg/mL)
IL-5 (pg/mL)
0 5 10 25 50 100
0 1.00 1.05 1.15 1.57 2.06 3.21
100 1.00 1.06 0.91 1.25 1.07 0.87
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Read Buffer T, and read on a Meso Scale SECTOR Imager Reader. The
sample signal was normalized to themean negative control signal (neg-
ative serum pool) on the plate as RECL values. This methodwas validat-
ed and deemed suitable for clinical sample testing.
2.9. Statistical analysis
Following industry practices, the screening cut point was calculated
to allow for 5% false positives, and conﬁrmation cut point allowing for
1% false positives (Shankar et al., 2008).
3. Results
3.1. IL-5 Induced ADA false positive result
In recent phase II studies, the initial anti-drug antibody assay result-
ed in an average of 45% conﬁrmed ADA positive in clinical samples. This
unusually elevated ADApositive ratewas not accompanied by any alter-
ation in PK/PD data, increased adverse events, or loss of efﬁcacy. As part
of the clinical protocol, IL-5 levels including both free IL-5 and
mepolizumab-bound IL-5 were measured in study subjects with a vali-
dated immunoassay (Table 1). The pre-dose serum IL-5 concentrations
were below the Lower Limit of Quantiﬁcation (LLQ = 7.8 pg/mL) inFig. 2. Evaluation of anti-IL-5 antibody competition againstMepolizumab on ﬂowbased assay. A
the beads and the presence of mepolizumabwas detected by PE labelledmouse anti human IgG
open green =MM550C had partial competition; open blue = Mab 205 was mepolizumab commost subjects with mean values below 10 pg/mL across placebo and
treatment groups (ranging from 94% to 96%). Following treatment of
mepolizumab, serum IL-5 concentrations increased by approximately
ten-fold from baseline across all three dose groups at week 16 (mean
values ranging from 102 to 111 pg/mL). The IL-5 concentrations
remained elevated at last dose - week 48 (mean values ranging from
91 to 108 pg/mL), and slightly decreased at follow-up visit - week 56
(meanvalues ranging from62 to70pg/mL).We suspected that elevated
IL-5 in treated subjects contributed to the elevated ADA positive rate.. Assay scheme. rhIL-5was conjugated to BD functional beads, mepolizumabwas added to
. B. Competition pattern. Solid purple= buffer; open pink=Mab605 had no competition;
petitive. C. Ranking of competition.
Table 3
Inhibition of IL-5 induced false positive by various anti-IL-5 antibodies. PC and IL-5 alone or in combinationwithmepolizumab and PC spiked sampleswere pre-incubatedwith 20 μg/mL of
mepolizumab, Mab205 (competitive antibody), MM550C (partial competitive antibody) or Mab605 (non-competitive antibody) at RT for 1 h; then processed for ADA screening assay.
Raw signals in ECL were reported in the table.
Sample Concentration Buffer Mepolizumab Mab205 MM550C Mab605
NC N/a 89 82 87 84 92
PC (afﬁnity puriﬁed rabbit anti- mepolizumab) 200 ng/mL 4299 88 4474 4429 4467
20 ng/mL 563 80 584 597 584
IL-5 500 pg/mL 1385 80 87 309 1432
200 pg/mL 601 70 83 167 622
50 pg/mL 216 73 80 104 223
IL-5 + mepolizumab 200 pg/mL + 200 ng/mL 311 71 84 145 328
IL-5 + mepolizumab + PC
200 pg/mL + 200 ng/mL + 200 ng/mL 795 73 520 599 804
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and looked at the total IL-5 levels in these two groups (Fig. 1). The ADA
positive group had more samples showing elevated IL-5 with a mean of
119 pg/mL, compared to a mean of 29 pg/mL in ADA negative group.
To conﬁrm our hypothesis of IL-5 dimers causing ADA false positive
signals, we spiked IL-5 into normal human serum for analysis with the
initial ADA screening and conﬁrmation assays (Table 2). The addition
of IL-5 resulted in an increase of assay signal. At 50 pg/mL IL-5, the signal
increased sufﬁciently to yield a positive response. Moreover, the IL-5 in-
duced positive response was completely inhibited by 100 μg/mL
mepolizumab, demonstrating that the IL-5 induced false positives
would have been conﬁrmed in the conﬁrmation assay. This data sup-
ported our hypothesis that the elevated levels of complexed IL-5 can
generate false positive responses in the ADA assay, and these false pos-
itives contributed to the previously reported elevated ADA rate in clini-
cal studies.
3.2. Anti-IL-5 antibody and mepolizumab competition evaluation
In order to inhibit IL-5 induced false positives, we assessed anti-IL-5
antibodies for amepolizumab competitive antibody.We tested antibod-
ies in two formats – ﬂow based competition and plate based competi-
tion assays.
For the ﬂow based competition assay, IL-5 was conjugated to BD
functional beads. The competition of test IL-5 antibody was assessed
by the decrease of mepolizumab binding (reﬂected by PE FMI) to IL-5
conjugated beads compared to binding in absence of anti-IL-5 antibody
(Fig.2 A). A total of nine anti-IL-5 antibodies were tested and demon-
strated three different competition proﬁles – strong competitive, partial
competitive, and non-competitive (Fig.2 B). The strongest target com-
petition relative to mepolizumab was antibody Mab205 (Fig.2 C). Anti-
body binding property can vary in different assay formats. To conﬁrm
the competition results from the ﬂow based assay, anti-IL-5 antibodies
were tested in plate based competition assay in which biotin labelled
IL-5 was pre-incubated with test antibody or buffer, then mixed with
sulfo tagged mepolizumab. The IL-5/mepolizumab complex wasTable 4
Pre-incubation time course evaluation for Mab205 in inhibition of IL-5 induced false ADA positi
pre-incubatedwith orwithout (w/o) 20 μg/mL ofMab205 for 1, 2, 3, or 4 h at RT; then processed
A cut point of RECL = 1.58 was applied. P = ADA positive, N = ADA negative.
1 h 2 h
W/o With ADA status W/o With ADA stat
Sample 1 22.54 2.13 P 22.94 2.05 P
Sample 2 11.29 5.52 P 11.33 5.40 P
Sample 3 7.64 1.22 N 7.79 1.16 N
Sample 4 4.43 1.08 N 4.59 1.11 N
Sample 5 3.03 1.89 P 3.03 1.77 P
Sample 6 8.31 2.67 P 8.76 2.38 P
Sample 7 10.60 8.50 P 10.98 8.54 P
Sample 8 2.04 1.63 P 2.03 1.60 Pcaptured to streptavidin coated plate. The decrease of signal in the pres-
ence of test antibody indicated a competition from test antibody. From
the 12 antibodies tested, Mab205 once again demonstrated the stron-
gest target competition relative to mepolizumab (Fig.3). Therefore,
Mab205 seemed to be the best candidate and was selected for further
evaluation to block IL-5 induced false ADA positive in the ADA assay.
3.3. Elimination of IL-5 interference by adding mepolizumab competitive
antibodies into assay diluent
3.3.1. Selection of Mab205 as the competitive IL-5 blocking antibody to in-
hibit IL-5 induced false positive
To test if Mab205 could inhibit IL-5 induced false ADA positive re-
sponse, we spiked IL-5 into NC alone, or with mepolizumab with or
without PC to mimic drug bound IL-5 scenarios in clinical samples. NC
and PC were included as controls for the assessment. All samples were
pre-incubated in buffer or buffer containing 20 μg/mL of inhibitory anti-
body (either mepolizumab, or Mab205, MM550C, Mab605), for 1 h at
RT. The pre-incubated samples were further analysed in ADA screening
assay (Table 3).While mepolizumab inhibited both PC and IL-5 induced
signals, Mab205 only selectively abolished IL-5 induced signal, and had
no impact on PC signal. Mab205 demonstrated complete inhibition of
IL-5 signal up to 500 pg/mL, which was the highest level we saw in
the dosed subjects. Mab205 inhibited drug bound IL-5 (IL-5 and
mepolizumab spiked serum) just as efﬁciently as it inhibited free IL-5.
MM550C, showed partial inhibition of IL-5 signal, and had no impact
on PC signal as well. Mab605 showed no inhibition in IL-5 induced sig-
nal, or PC signal. As a result, Mab205was selected as the target compet-
itive antibody to inhibit IL-5 induced false ADA positives.
3.3.2. Pre-incubation time course
To ﬁnd the optimal pre-incubation time to inhibit IL-5 induced false
positives, ADA screening positive samples (eight) were pre-incubated
with or without 20 μg/mL Mab205 for various incubation times – 1, 2,
3, or 4 h at RT. The pre-incubated samples were analysed in the ADA
screening assay. There was a signiﬁcant decrease in assay response inve. Eight study samples with positive ADA response from initial ADA screening assay were
for ADA screening assay. Normalized assay signal to NC (RECL)were reported in the table.
3 h 4 h
us W/o With ADA status W/o With ADA status
17.05 1.55 N 18.67 1.80 P
8.56 3.98 P 9.27 4.44 P
5.94 0.99 N 6.61 1.08 N
3.68 0.95 N 3.87 0.99 N
2.36 1.36 N 2.60 1.58 P
6.75 2.04 P 7.86 2.42 P
9.81 7.74 P 10.29 9.73 P
1.70 1.38 N 1.87 1.56 N
Table 5
Selection of optimal Mab205 concentration. Various concentrations of Mab205 was pre-
incubated with NC, 1000 pg/mL IL-5, or 6 ADA positive samples at RT for 3 h, then proc-
essed for ADA screening assay. Normalized assay signal to NC (RECL) were reported in
the table. A cut point of RECL = 1.58 was applied.
Buffer Mab205 (μg/mL)
2 μg/mL 10 μg/mL 20 μg/mL 50 μg/mL 100 μg/mL
NC 1.05 1.02 0.98 0.96 0.99 0.99
IL-5 (1000 pg/mL) 47.07 11.92 2.22 1.44 1.08 0.99
Sample 9 5.58 3.32 1.38 1.12 0.96 0.91
Sample 10 6.26 3.31 1.45 1.20 1.04 1.00
Sample 11 1.83 1.43 1.07 0.99 0.98 0.95
Sample 12 1.80 1.31 0.95 0.89 0.92 0.90
Sample 13 4.05 2.57 1.33 1.14 1.03 1.04
Sample 14 4.10 2.21 1.31 1.15 1.05 1.10
20 K. Liao et al. / Journal of Immunological Methods 441 (2017) 15–23the presence of IL-5 blocking antibody even with 1 h pre-incubation.
However, optimal inhibition was observed at 3 h pre-incubation with
most samples becoming ADA negative. With a 3 h pre-incubation, 5
out of the 8 samples became ADA negative compared to 2 samples
from the 1 h and 2 h pre-incubations and 3 samples from the 4 h pre-in-
cubation becomingnegative, respectively (Table 4). Based on this obser-
vation, we selected the 3 h Mab205 pre-incubation to inhibit IL-5
interference in ADA detection.
3.3.3. Selection of optimal blocking antibody concentration
Toﬁnd the optimal concentration ofMab205 for inhibition of IL-5 in-
duced false positives, we spiked 1000 pg/mL IL-5 (2 times over the
highest IL-5 level observed in dosed subjects) in serum and selected
clinical samples (six) thatwere positive in the initial ADA assay for anal-
ysis. These samples were pre-incubated with various concentrations of
IL-5 blocking antibody (2, 10, 20, 50 and 100 μg/mL) for 3 h at RT, and
then analysed in the ADAassay (Table 5). As IL-5 blocking antibody con-
centration increased, the decrease of signal was observed in both the IL-
5 spiked sample and 6 clinical samples. While 20 μg/mL IL-5 blocking
antibody reduced the interference to background in the clinical samples,
the 1000 pg/mL IL-5 spiked sample required 50 μg/mL IL-5 blocking
antibody. The 100 μg/mLof IL-5 blocking antibody had an almost identi-
cal inhibitory proﬁle as 50 μg/mL. Based on this result, we selected
50 μg/mL concentration of Mab205 for sample pre-incubation to inhibit
IL-5 induced false positives in the modiﬁed ADA assay.
3.3.4. The presence ofMab205 in assay buffer had no impact on ADAdetection
and conﬁrmation
To evaluate whether the in-solution IL-5 blocking antibody inter-
fered with ADA detection and conﬁrmation, ADA positive and negative
clinical samples (ﬁve), along with NC and PC (200 pg/mL andTable 6
Thepresence ofMab205 in assay buffer had no impact onADAdetection and conﬁrmation.
Assay controls (NC, HPC, & LPC) and randomly selected study samples were tested in par-
allel at conditions with or without Mab205 (initial vs. modiﬁed assay condition). A cut
point of RECL = 1.58 and conﬁrmation cut point of 30.3% inhibition were applied for
ADA status interpretation, which were established from assay validation. P = ADA posi-
tive, N = ADA negative.
Sample ID Test in buffer Test in buffer with 50 μg/mL
Mab205
Screen
(RECL)
Conﬁrmation
(RECL)
ADA
Status
Screen
(RECL)
Conﬁrmation
(RECL)
ADA
Status
NC 1.00 1.00 N 1.00 1.00 N
500 ng/mL PC 153.02 1.06 P 157.87 1.04 P
20 ng/mL PC 6.94 0.98 P 7.23 0.97 P
Sample 15 1.98 1.07 P 1.17 1.04 N
Sample 16 5.43 1.03 P 1.87 1.23 P
Sample 17 6.75 1.23 P 5.69 1.32 P
Sample 18 1.59 0.84 P 1.31 0.99 N
Sample 19 1.02 0.94 N 1.04 1.05 N20 pg/mL) were pre-incubated with 50 μg/mL Mab205 at RT. After 3 h,
samples were processed for ADA screening and conﬁrmation analysis
(Table 6). The NC and two PC samples performed the same in the mod-
iﬁed and initial ADA assays with similar raw (data not shown) and RECL
in responses. The negative ADA sample remained negative in the mod-
iﬁed assay. Two ADApositive samples, with initial ADAmethod, became
ADA negative in the modiﬁed assay. Two other ADA positive samples
remained screening positive andwere further conﬁrmed. The data indi-
cated the modiﬁed ADA assay had no impact in ADA detection and
conﬁrmation.
3.4. Inhibition of IL5 Interference by solid phase extraction of drug target
Thirteen commercial anti IL-5 antibodies were evaluated in solid-
phase IL-5 extraction for reduction of IL-5 induced false positive assay
responses, including ﬁve monoclonals, four biotinylated monoclonals
and four polyclonals. As shown in Fig. 4, one label free antibody
(MM550C) and one biotin labelled antibody (554491) completely sup-
pressed both free IL-5 and drug bound IL-5 assay interference. Three an-
tibodies showed partial reduction in IL-5 induced signals, and eight
antibodies showed no reduction in IL-5 induced signals. Mab205,
which demonstrated the best inhibitory effect for IL-5 signals for in-so-
lution inhibition was not the most effective in IL-5 depletion when
adsorbed in a well, and the biotinylated MM550C didn't work as effec-
tively as the label-free form. Based on these ﬁndings, the biotinylated
monoclonal antibody (554491) was selected for further evaluation to
deplete IL-5 induced assay signal.
3.5. Comparison of in-solution inhibition and solid-phase IL-5 depletion
To compare the efﬁciency in eliminating IL-5 induced false positives,
the in-solution IL-5 inhibition and solid-phase IL-5 depletion methods
were applied to a panel of clinical samples. ADApositive clinical samples
(79) from the initial ADA assaywere randomly selected and re-analysed
using both conditions (Fig. 5). While 24 samples remained positive in
solid-phase IL-5 depletion, only 14 samples remained positive with
the in-solution inhibition. Additionally, the in-solution IL-5 inhibition
had a lower background signal with a mean 1.08 RECL in negative sam-
ples compared to a mean 1.24 RECL in solid-phase IL-5 depletion. Com-
paratively, the in-solution inhibition ADAmethod demonstrated amore
complete inhibition of IL-5 interference than solid-phase depletion.Fig. 4. Evaluation of anti-IL-5 antibodies for IL-5 depletion to reduce false ADA response.
Monoclonal (left side), polyclonal (right side) and biotinylated monoclonal (middle:
“bt”). Anti-IL-5 antibodies were adsorbed or bound to well surfaces. The IL-5
(500 pg/mL) and IL-5/drug (500 pg/mL/100 ng/mL) spiked serum samples were diluted
(1:10) and incubated in the anti-IL-5 antibody coated wells for 4 h. The supernatant
(IL-5 depleted) was tested with the initial ADA assay.
Fig. 5.Effectiveness comparisonbetween IL-5 inhibition and IL-5 depletion to remove IL-5 induced falseADApositive. A. Randomly selected samples that conﬁrmedpositivewith the initial
assaywere re-analysed in themodiﬁed ADA screening assay using solid phase IL-5 depletion and in-solution IL5 inhibition. B. Summary of assay result,mean RECL of positive and negative
samples from the three assay formats.
21K. Liao et al. / Journal of Immunological Methods 441 (2017) 15–23Moreover, the in-solution inhibition ADA assay was simpler to perform
and the assay variation was reduced compared to the solid-phase IL-5
depletion method. Based on these results, we decided to adopt the in-
solution inhibition ADA method for clinical sample testing.
3.6. ADA testing result with modiﬁed ADA method
Having resolved the IL-5 induced false positive issue,we re-analysed
the ADA samples from two phase II studieswith the improvedmodiﬁed
ADA assay. With the initial ADA method, 49% of samples screened pos-
itive and 45% of subjects conﬁrmed positive. In contrast, re-analysis
with themodiﬁedmethod resulted in 13% of samples screening positive
and 5% of samples conﬁrming positive (Table 7). No neutralizing ADAs
were found from either ADA method tested positive samples.
Three phase III study samples were tested only with the modiﬁed
ADA method. From 4270 analysed samples, the combined ADA screen-
ing positive rate was 25% and the combined ADA conﬁrming positive
rate was 2% (Table 7). There was one subject that developed neutraliz-
ing antibodies at two time points, that also had decreased PK drug con-
centrations and adverse clinical observations.
4. Discussion
An electroluminescence bridging assay is a commonly used method
for ADA detection. One advantage is its superior sensitivity, often
reaching single digits in ng/mL rangewith afﬁnity puriﬁed positive con-
trols. However, these assays are susceptible to various forms of drug tar-
get related false positives (e.g. membrane bound receptors on cell
fragments ormultivalent targets) or non-speciﬁc antibodies. This is par-
ticularly truewhen the target ismultivalent since this allows for binding
of multiple drug molecules and results in a complex bridge that is inde-
pendent of ADAs.
For mepolizumab, the target IL-5 is a homodimer (Milburn et al.,
1993). Knowing this property of IL-5, we evaluated the possibility of
IL-5 induced false positives in early assay development. At endogenous
IL-5 levels observed in asthma patient, the IL-5 interference did not pro-
duce a positive assay response and was not considered an issue at theTable 7
ADA results from two Phase II and three Phase III studies with initial ADA assay and modiﬁed
Combined Phase II data
Initial assay Modiﬁed Mab205 in-solutio
Sample size 3052 3052
Screen positive (%) 49% 13%
Conﬁrmed positive (%) 45% 5%
Neutralizating positive n (%) 0(0%) 0(0%)time of assay development. However, the IL5 biomarker analysis during
several Phase II studies revealed target (IL-5) accumulation in dosed
subjects (up to 100 fold increase). The accumulated IL-5 was drug-
bound since free IL-5 was not detected in these samples (majority
below the lower limit of quantiﬁcation at 3.91 pg/mL - data not
shown).While binding ofmepolizumab to IL-5 prevents IL-5 from bind-
ing to its receptor, it may also protect IL-5 from its natural clearance or
degradation process by ubiquitous proteolytic enzymes, and results in
elevated levels of drug-bound IL-5 in the clinical samples. This became
problematic for the in vitro ADA assay during clinical sample testing,
since it is likely that the dilutions and incubations of the assay process
allowed the accumulated drug-bound IL-5 to dissociate and re-associate
with the biotin- and tag-labelled mepolizumab molecules, causing the
increased ADA positive rate (i.e. false positive). To eliminate target in-
terference, we tried two pre-treatment approaches – target inhibition
with an in-solution IL-5 blocking antibody or target removalwith an an-
tibody based solid-phase extraction. For eithermethod, the competitive
antibody was critical. From our experience, the antibody binding prop-
erty may vary in different formats (e.g. binding in solid phase may be
different from binding in solution). Therefore, we designed various
assay formats to evaluate the competition for IL5 against mepolizumab.
The bead based ﬂow competition assay seemed to be more sensitive
in detecting the competition. It required only 5-fold over-loading of the
competitive antibody (10 μg/mL competitive antibody to 2 μg/mL
mepolizumab) to show signal inhibition; while in plate based competi-
tion assays, a 300 fold over-loading (20 μg/mL competitive antibody to
62.5 ng/mLmepolizumab)was required to show complete competition.
The consistent competition property ofMab205 suggested thatMab205
and mepolizumab had similar binding epitope(s) to IL-5. Mab205 also
demonstrated similar afﬁnity in binding to IL-5 with Kd within 5% dif-
ference from mepolizumab (data not shown). Such properties made
Mab205 the best candidate for the application of eliminating IL-5 in-
duced false positive.
Mab205 was found to be the most effective antibody to inhibit IL-5
induced assay false positive signals in both IL-5 spiked serum and clini-
cal samples, andwas also the best anti-IL-5 antibody for in-solution IL-5
inhibition. Interestingly,Mab205was not themost efﬁcient antibody forMab205 in-solution inhibition ADA assay.
Combined Phase III data
n inhibition ADA assay Modiﬁed Mab205 in-solution inhibition ADA assay
4270
25%
2%
2(0%)
22 K. Liao et al. / Journal of Immunological Methods 441 (2017) 15–23IL-5 depletion. Based on our experimental ﬁndings, we employed a dif-
ferent anti-IL-5 antibody for in-solution inhibition (Mab205) and target
depletion (554491). We thoroughly investigated the two methods for
the ability to eliminate IL-5 induced ADA signals using both IL-5 spiked
serum and clinical samples. While both formats were effective in re-
ducing IL-5 false positive responses in IL-5 spiked serum samples,
the in-solution inhibition was more effective in blocking IL-5 in-
duced signals and reducing false positive results in clinical samples.
One reason for the better result with the in-solution IL-5 inhibition
was that a greater excess of IL-5 blocking antibody can be achieved
with the in-solution inhibition method. For example, if a sample
has IL-5 level of 500 pg/mL, an estimated 3.5 – or 4.6 × 103 M excess
of competitive antibody could be achieved in streptavidin coated
plates or streptavidin – coated Sepharose resin, respectively. The
in-solution inhibition had an estimated of 7 × 104 fold molar excess
of competitive IL-5 blocking antibody.
The use of resin for IL-5 depletion introduced several challenges, in-
cluding achieving consistent bead number to multiple samples, and the
risk of transferring resin material for additional interference. These
technical issues could have been overcome with ﬁlter plates or
streptavidin coated magnetic beads to remove the depleting IL-5 anti-
body from subsequent steps. In addition to the technical issues, the
solid-phase target depletion may carry the risk of depleting binding
ADA along with the target-drug immune complex from samples.
While there was an initial concern about adding a competitive IL-5
blocking antibody directly to the sample and having it remains in
the sample during the ADA detection process, results conﬁrmed
that adding Mab205 to the samples had no impact on the NC signal,
PC detection or PC conﬁrmation in either individual serum or pooled
serum (validation data, data not shown). Mab205 is a mouse mAb
with different framework than drug, and thus unlikely to cross
react with humanized IgG1 drug reacting ADA to generate a false
negative result. Compared to the technical challenges in IL-5 deple-
tion methods, Mab205 in-solution inhibition was simple to execute
and required the least modiﬁcations to the initial assay procedures.
Assay validation showed similar drug tolerance and sensitivity, and
other assay parameters between the initial and the modiﬁed in-solu-
tion inhibition ADA method.
With the validated modiﬁed assay, we re-analysed two phase II
clinical samples. The conﬁrmed positive rate was decreased from
45% with initial ADA assay to 5% with the modiﬁed assay (mean of
two studies). The initial data grossly overestimated the ADA rate
for this drug and the commonly used drug competitive conﬁrmation
method could not differentiate between true ADA responses and
multimeric target induced false positive responses. Fortunately, the
neutralization assay suggested that the ADA rate was not as high
since no neutralizing antibodies were detected in these conﬁrmed
ADA positive samples. Further, the reporting of false ADA data
could be misleading for physicians and patients. Therefore, the mod-
iﬁed assay was used for sample testing in all phase III studies and re-
sulted in a combined conﬁrmed ADA positive rate of 2% across three
phase III studies. Among the identiﬁed ADA positive samples by the
modiﬁed ADA assay, two samples from one subject were tested to
be neutralizing in the NAb assay.
We tested IL-5 interference for detection of neutralizing ADA in the
neutralizing antibody (NAb) assay, and found that IL-5 had no impact
on neutralizing ADA detection up to 2000 pg/mL (Data not shown).
The different impact of elevated IL-5 on ADA and NAb assay may be at-
tributable to factors such as assay design, sample dilution, reagent con-
centrations for the ADA and NAb assay.
Target interference is a fairly common problem facing immuno-
genicity testing. Here, we reported our experience in identifying
and resolving IL-5 induced false positive results in clinical sample
testing. Our approach in resolving this target interference could be
useful for similar challenges. Overall, our revised ADA method is ab-
solutely critical for establishing correct ADA positive rates withindosed subjects and will be necessary for all assessments of
mepolizumab immunogenicity.
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